A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma

Resistance to these agents develops frequently, and their use is often limited by intolerance.05/01/2014
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news